Show simple item record

dc.contributor.authorKoutsoudakis, George
dc.contributor.authorRomero-Brey, Inés
dc.contributor.authorBerger, Carola
dc.contributor.authorPérez-Vilaró, Gemma
dc.contributor.authorMonteiro Perin, Paula
dc.contributor.authorVondran, Florian Wolfgang Rudolf
dc.contributor.authorKalesse, Markus
dc.contributor.authorHarmrolfs, Kirsten
dc.contributor.authorMüller, Rolf
dc.contributor.authorMartinez, Javier P
dc.contributor.authorPietschmann, Thomas
dc.contributor.authorBartenschlager, Ralf
dc.contributor.authorBrönstrup, Mark
dc.contributor.authorMeyerhans, Andreas
dc.contributor.authorDíez, Juana
dc.date.accessioned2015-09-18T09:08:09Zen
dc.date.available2015-09-18T09:08:09Zen
dc.date.issued2015-06-10en
dc.identifier.citationSoraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. 2015: J. Hepatol.en
dc.identifier.issn1600-0641en
dc.identifier.pmid26070407en
dc.identifier.doi10.1016/j.jhep.2015.06.002en
dc.identifier.urihttp://hdl.handle.net/10033/577529en
dc.description.abstractSoraphen A (SorA) is a myxobacterial metabolite that inhibits the acetyl-CoA carboxylase, a key enzyme in lipid biosynthesis. We have previously identified SorA to efficiently inhibit the human immunodeficiency virus (HIV). The aim of the present study was to evaluate the capacity of SorA and analogues to inhibit hepatitis C virus (HCV) infection.
dc.languageENGen
dc.titleSoraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.en
dc.typeArticleen
dc.contributor.departmentTWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen Str. 7, 30625, Hannover, Germany.en
dc.identifier.journalJournal of hepatologyen
refterms.dateFOA2016-10-15T00:00:00Z
html.description.abstractSoraphen A (SorA) is a myxobacterial metabolite that inhibits the acetyl-CoA carboxylase, a key enzyme in lipid biosynthesis. We have previously identified SorA to efficiently inhibit the human immunodeficiency virus (HIV). The aim of the present study was to evaluate the capacity of SorA and analogues to inhibit hepatitis C virus (HCV) infection.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Koutsoudakis et al_final.pdf
Size:
221.4Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
Figure1_RS_NEW.pptx
Size:
143.1Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 1
Thumbnail
Name:
Supplementary_SoraphenA_FINAL.docx
Size:
295.1Kb
Format:
Microsoft Word 2007
Description:
supplemental materials
Thumbnail
Name:
Figure2_RS_NEW.pptx
Size:
127.6Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 2
Thumbnail
Name:
Figure3_RS.pptx
Size:
55.33Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 3
Thumbnail
Name:
Figure4_RS.pptx
Size:
553.2Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 4
Thumbnail
Name:
Figure5_RS.pptx
Size:
717.9Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 5
Thumbnail
Name:
Figure6_RS.pptx
Size:
2.662Mb
Format:
Microsoft PowerPoint 2007
Description:
figue 6
Thumbnail
Name:
Figure7_RS.pptx
Size:
47.70Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 7
Thumbnail
Name:
Figure8_RS.pptx
Size:
92.86Kb
Format:
Microsoft PowerPoint 2007
Description:
figure 8

This item appears in the following Collection(s)

Show simple item record